# DAREON-NEC-1 (NCT07544654)

> DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07544654
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Boehringer Ingelheim
- Conditions: Extrapulmonary Neuroendocrine Cancer (epNEC)
- Interventions: Obrixtamig; Carboplatin; Etoposide; Ventana DLL3 RxDx assay
- Enrollment: 390
- Primary outcome: Overall survival (OS)

## Indexed commentary on DAREON-NEC-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- YouTube: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=dareon-nec-1-nct07544654